SR 48692

Subscribe to Selected New Research on SR 48692

11 relevant articles (1 outcomes, 3 trials/studies) found for this Bio-Agent

Description: structure given in first source; a neurotensin receptor antagonist

Also Known As:

2-((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid; SR-48692; Tricyclo(3.3.1.13,7)decane-2-carboxylic acid, 2-(((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)-

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Azoles: 224

Pyrazoles: 17

SR 48692: 11

2-Ring Heterocyclic Compounds

Quinolines: 58

SR 48692: 11

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 10/01/1995 - "It is suggested that the neurotensin receptor antagonist SR 48692 may be useful in the treatment of pancreatic cancers that possess this type of neurotensin receptor." 10/01/1995 - "Pharmacological characterization of SR 48692 sensitive neurotensin receptor in human pancreatic cancer cells, MIA PaCa-2." 01/01/1999 - "Neurotensin receptor-mediated inhibition of pancreatic cancer cell growth by the neurotensin antagonist SR 48692." 01/01/1999 - "Second messenger calcium responses to the neuropeptide neurotensin and its non-peptide antagonist SR 48692 were studied in relation to the proliferation of pancreatic cancer cells" Get all the results and reference details, order at left...
2.	Dyskinesias (Dyskinesia) 05/01/2004 - "This study evaluated the effects of these three antagonists of the NK3 (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease" Get all the results and reference details, order at left...
3.	Shock 02/08/2002 - "By use of the NT antagonist, SR 48692, the present study examines the involvement of endogenous NT in modulating the preferential activation of MRN 5-HT neurons by sound stress, and extends the findings with sound stress to two other stressors (swim and tail shock)" Get all the results and reference details, order at left...
4.	Parkinson Disease (Parkinson's Disease) 05/01/2004 - "This study evaluated the effects of these three antagonists of the NK3 (SR 142801), neurotensin (SR 48692), and cannabinoid (SR 141716) receptors on the severity of motor symptoms and levodopa-induced dyskinesias after administration of a single dose of levodopa in 24 patients with Parkinson disease" Get all the results and reference details, order at left...
5.	Carcinoma (Carcinomatosis) 01/01/1993 - "In a cell line derived from a human colon carcinoma (HT-29), SR 48692 competitively antagonizes neurotensin-induced intracellular Ca2+ mobilization with a pA2 (-log Kapp) values of 8.13 +/- 0.03, which is consistent with results obtained in binding studies" Get all the results and reference details, order at left...
11 Diseases and 11 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Neurotensin Receptors (Neurotensin Receptor)
2.	Neurotensin
3.	Serotonin (5 Hydroxytryptamine)
4.	Levodopa (L Dopa)
5.	SR 142801 (osanetant)
6.	rimonabant
7.	Dopamine (Intropin)
8.	SR 142948A
9.	Neuropeptides
10.	Morphine (MS Contin)
14 Drugs and Important Bio-Agents and 11 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Analgesia
1 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>